Illumina, Inc. (NASDAQ:ILMN) Given Consensus Recommendation of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMNGet Rating) has been given a consensus rating of “Hold” by the eighteen analysts that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $257.27.

Several equities research analysts have recently commented on the stock. Citigroup lowered their price target on shares of Illumina from $220.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, August 12th. Credit Suisse Group assumed coverage on shares of Illumina in a research report on Wednesday, August 24th. They set a “neutral” rating and a $230.00 price target for the company. Barclays lowered their price target on shares of Illumina to $130.00 in a research report on Monday, August 15th. Stifel Nicolaus lowered their price target on shares of Illumina from $480.00 to $300.00 and set a “buy” rating for the company in a research report on Friday, August 12th. Finally, Bank of America lowered their price target on shares of Illumina from $220.00 to $200.00 in a research report on Friday, August 12th.

Illumina Trading Down 2.4 %

Shares of NASDAQ ILMN opened at $193.49 on Friday. Illumina has a 1-year low of $173.45 and a 1-year high of $436.95. The company has a market cap of $30.40 billion, a PE ratio of -3,224.30, a P/E/G ratio of 2.23 and a beta of 1.16. The company has a current ratio of 1.00, a quick ratio of 0.82 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average of $206.99 and a two-hundred day moving average of $247.75.

Illumina (NASDAQ:ILMNGet Rating) last announced its earnings results on Thursday, August 11th. The life sciences company reported $0.57 earnings per share for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.06). Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same period in the prior year, the firm posted $1.87 earnings per share. The company’s revenue was up 3.2% on a year-over-year basis. As a group, equities analysts expect that Illumina will post 2.81 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, SVP Alexander Aravanis sold 539 shares of Illumina stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total value of $107,800.00. Following the transaction, the senior vice president now owns 3,346 shares of the company’s stock, valued at $669,200. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Institutional Trading of Illumina

A number of institutional investors have recently made changes to their positions in ILMN. Schroder Investment Management Group lifted its position in shares of Illumina by 0.7% in the fourth quarter. Schroder Investment Management Group now owns 45,213 shares of the life sciences company’s stock worth $17,201,000 after purchasing an additional 324 shares in the last quarter. Public Sector Pension Investment Board lifted its position in shares of Illumina by 5.4% in the fourth quarter. Public Sector Pension Investment Board now owns 26,079 shares of the life sciences company’s stock worth $9,921,000 after purchasing an additional 1,340 shares in the last quarter. Fiduciary Trust Co. lifted its position in shares of Illumina by 32.0% in the fourth quarter. Fiduciary Trust Co. now owns 816 shares of the life sciences company’s stock worth $311,000 after purchasing an additional 198 shares in the last quarter. Mutual Advisors LLC lifted its position in shares of Illumina by 12.2% in the fourth quarter. Mutual Advisors LLC now owns 578 shares of the life sciences company’s stock worth $220,000 after purchasing an additional 63 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Illumina in the fourth quarter worth $253,000. Institutional investors own 86.12% of the company’s stock.

About Illumina

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Further Reading

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.